Immune Systems Advisor

Early treatment is critical and the most important factor in managing this disease. COVID-19 is a clinical diagnosis; a confirmed antigen or PCR test is not required. Treatment should be initiated immediately after the onset of flu-like symptoms. The multiple therapies and drugs in this protocol have different mechanisms of action and work synergistically during various phases of the disease. About I-CARE Protocol The information in this document is our recommended approach to COVID-19 based on the best (and most recent) literature. It is provided as guidance to healthcare providers worldwide on the early treatment of COVID-19. Patients should always consult with their provider before starting any medical treatment. Updates:  The Stratus Variant (XFG): Symptoms, Global Spread, and Impact in Late 2025 Note: According to Dr Pierre Kory, "...highlighting his objectivity, while Pierre Kory was once the leading advocate for ivermectin to treat COVID, he no longer does as the newer vari...

As I reported a few days ago, a recent peer-reviewed study revealed a deeply alarming finding: 100% of the vaccinated participants examined had amyloid fibrin(ogen) microclots circulating in their blood. These are the same Thioflavin-T–positive, β-sheet, fibrinolysis-resistant clots now widely observed in Long VACCINE and Long COVID patients due to spike protein exposure. The anomalous microclots also appear to be behind the long white fibrous clots being pulled out of corpses by the majority of embalmers worldwide. Their presence in every vaccinated individual tested underscores a crisis that the medical establishment has yet to acknowledge — and one that now demands immediate scientific attention. If they are as widespread as early data suggests, then the most urgent question now becomes: How do we degrade them? Nattokinase Breaks Down Amyloid Microclots A recent peer-reviewed study by Grixti et al , published in the Journal of Experimental and Clinical Application of Chinese Medic...